GlassScriptPhysician profile
Amanda J Baxa
NPI 1366703100
$615.93
in general payments reported to CMS, 2019-2025
18 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.79 · 2020: $27.56 · 2022: $31.36 · 2023: $144 · 2024: $189 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $510.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $87.54 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $81.56 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $64.69 | 2019-2025 | |
| Dexcom, INC. | $56.44 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $49.75 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $49.33 | 2022-2024 | Evenity, Prolia |
| Abbvie INC. | $32.46 | 2023 | Ubrelvy |
| Medtronic, INC. | $26.44 | 2025 | Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $22.78 | 2024 | |
| Phathom Pharmaceuticals, INC. | $21.27 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $18.59 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.73 | 2024 | Synjardy, Jardiance |
| Glaxosmithkline, LLC. | $16.28 | 2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $16.18 | 2020 | |
| Mylan Specialty L.P. | $15.62 | 2023 | Yupelri |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $14.50 | 2025 | Contrave |
| Bayer Healthcare Pharmaceuticals INC. | $14.39 | 2024 | |
| Sanofi-Aventis U.S. LLC | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Baxa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.